Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.10.

Several equities analysts recently weighed in on APLT shares. Citigroup cut their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Royal Bank of Canada cut their price target on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a report on Friday, December 20th. UBS Group restated a “neutral” rating and issued a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. William Blair cut shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Finally, Robert W. Baird reduced their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a report on Friday, November 29th.

Applied Therapeutics Price Performance

Applied Therapeutics stock opened at $0.57 on Friday. Applied Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $10.62. The firm has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $4.81. The firm has a market cap of $65.77 million, a price-to-earnings ratio of -0.35 and a beta of 1.88.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ground Swell Capital LLC bought a new stake in Applied Therapeutics in the 4th quarter valued at $27,000. Toronto Dominion Bank acquired a new stake in shares of Applied Therapeutics during the 4th quarter valued at about $27,000. SG Americas Securities LLC increased its stake in Applied Therapeutics by 169.0% in the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares during the period. Private Advisor Group LLC acquired a new position in Applied Therapeutics in the fourth quarter worth about $35,000. Finally, Intech Investment Management LLC lifted its stake in Applied Therapeutics by 176.1% during the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock worth $45,000 after purchasing an additional 33,567 shares during the period. 98.31% of the stock is owned by institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.